We also analyzed RIP1, RIP3, and MLKL concentration according to NAFLD activity score (NAS) in patients with NASH (n = 30, 1 patient in our cohort did not have a recorded NAS), and found MLKL, but not RIP1 or RIP3, was higher in patients with NAS greater than or equal to 3 than those with NAS less than 3 (Supplemental Figure 2). This evidence concerns the gene MLKL and metabolic dysfunction-associated steatotic liver disease.